| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9327640 | Gynecologic Oncology | 2005 | 6 Pages |
Abstract
Even in the absence of co-morbidity, standard combination therapy was prescribed significantly less often for elderly patients with FIGO II or III ovarian cancer. Age and combined treatment of surgery and platinum-based chemotherapy were independent prognostic factors. Co-morbidity did not seem to have a prognostic effect.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
H.A.A.M. Maas, R.F.P.M. Kruitwagen, V.E.P.P. Lemmens, S.H. Goey, M.L.G. Janssen-Heijnen,